Cancer News and Research

Latest Cancer News and Research

Akela reports net income of $1.5 million for three months ended December 31, 2010

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months and year ended December 31, 2010.

1 Apr 2011

NCI awards Case Western Reserve with $1.6 million grant for cancer research

Case Western Reserve University School of Medicine has received a $1.6 million grant from the National Cancer Institute to study how tumor cells avoid detection by the body's immune system, allowing cancer to develop and spread.

1 Apr 2011

Mitomics introduces new test to detect prostate cancer

Mitomics, world leader in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, announced today the launch of its flagship product, the Prostate Core Mitomic Test, a revolutionary new test that uses the science of mitochondrial DNA to accurately determine the absence or presence of cancerous cells using previously obtained prostate biopsy tissue.

1 Apr 2011

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

1 Apr 2011

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..

31 Mar 2011

Asuragen launches new miRNA Biofluids service offering

Asuragen, Inc. announced today the launch of its new miRNA Biofluids service offering designed to interrogate miRNAs from serum, plasma, cerebral spinal fluid, and urine. Supported by a growing body of literature, the utility of miRNA biomarkers in biofluids has been demonstrated for numerous disease areas including Cancer, Neurology, Autoimmune, and Cardiovascular diseases.

31 Mar 2011

Clontech launches new SMARTer Ultra Low RNA Kit

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.

31 Mar 2011

First Edition: March 31, 2011

In today's news, reports on continuing congressional efforts to reach a deal on the current-year budget and on a move by Medicare to cover Provenge, a prostate cancer drug.

31 Mar 2011

Protox reports net loss of $4.5 million for year ended December 31, 2010

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced financial results and achievements for the year ended December 31, 2010.

31 Mar 2011

Insight into bowel cancer

Stem cells in the intestine, which when they mutate can lead to bowel cancers, might also be grown into transplant tissues to combat the effects of those same cancers, the UK National Stem Cell Network annual science meeting will hear today.

31 Mar 2011

RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.

31 Mar 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

Cancer Commons researchers publish MDMM paper in PLoS ONE journal

Cancer Commons, an initiative of CollabRx, a provider of information technology to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model of melanoma which classifies the disease into molecular subtypes, rather than traditional histological or cellular subtypes, and describes treatment guidelines for each subtype, including specific assays, drugs, and clinical trials.

31 Mar 2011

Study finds continued smoking after cancer diagnosis among patients, family caregivers

Nicotine is so addictive for many people that even a cancer diagnosis doesn't help them - or their family members and caregivers - throw the cigarettes away.

31 Mar 2011

mtm’s p16 and Ki-67 dual staining test identifies high-grade cervical disease in women with ASC-US and LSIL

mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the publication of a new paper showing that dual staining for p16 and Ki-67 can pinpoint the underlying high-grade cervical disease with a high degree of sensitivity and specificity in women with ASC-US or LSIL cytology results.

31 Mar 2011